Michael Cyprys

Apr 21, 2026

Target

$184.00

Current

$128.99

Performance

—

Michael Cyprys rated BX as Overweight on Apr 21, 2026, setting a price target of 184. Shares have remained stable near 128.99, leaving the 184 target still in play.

BN

Apr 21, 2026

Target

$61.00

Current

$46.66

Performance

—

On Apr 21, 2026, BN was given a Overweight rating by Michael Cyprys, with a target price of 61. The stock traded sideways with a % move, keeping the bullish thesis unresolved.

BAM

Apr 21, 2026

Target

$62.00

Current

$49.05

Performance

—

BAM received a Equal-Weight rating from Michael Cyprys on Apr 21, 2026, aiming for 62. Shares remained flat at 49.05, aligning with the neutral rating.

ARES

Apr 21, 2026

Target

$163.00

Current

$118.77

Performance

—

On Apr 21, 2026, Michael Cyprys published a Equal-Weight outlook on ARES, with a target of 163. Sideways action left the Hold view intact, with no major move since 118.77.

APO

Apr 21, 2026

Target

$165.00

Current

$127.33

Performance

—

Michael Cyprys on Apr 21, 2026 assigned APO a Overweight rating, with a price target of 165. The recommendation remains pending validation as shares consolidate around 127.33.

SCHW

Apr 17, 2026

Target

$125.00

Current

$93.15

Performance

0.94%

On Apr 17, 2026, Michael Cyprys reaffirmed SCHW with a Overweight rating, targeting 125. Market indecision has kept the 125 target in a holding pattern.

AMP

Apr 10, 2026

Target

$452.00

Current

$456.59

Performance

2.30%

AMP was rated Underweight by Michael Cyprys on Apr 10, 2026, with a price objective of 452. The expected decline hasn’t materialized, as shares trade near 456.59.

CBOE

Apr 10, 2026

Target

$273.00

Current

$305.16

Performance

3.11%

On Apr 10, 2026, Michael Cyprys initiated coverage on CBOE with a Underweight rating and target of 273. Sideways trading kept the bearish case unconfirmed with the stock at 305.16.

CME

Apr 10, 2026

Target

$362.00

Current

$287.45

Performance

-2.66%

Michael Cyprys issued a Overweight recommendation for CME on Apr 10, 2026, price target set at 362. The target of 362 remains in play, though confirmation will depend on future moves.

GEMI

Apr 10, 2026

Target

$6.00

Current

$4.67

Performance

5.66%

On Apr 10, 2026, GEMI was evaluated by Michael Cyprys, who gave a Equal-Weight rating and target of 6. Investors who stayed in despite the Hold saw upside of 5.66%.

HOOD

Apr 10, 2026

Target

$95.00

Current

$91.28

Performance

31.92%

Michael Cyprys rated HOOD as Equal-Weight on Apr 10, 2026, setting a price target of 95. Despite the Hold call, shares climbed 31.92% to 91.275, revealing unexpected momentum.

ICE

Apr 10, 2026

Target

$187.00

Current

$160.61

Performance

0.01%

On Apr 10, 2026, ICE was given a Equal-Weight rating by Michael Cyprys, with a target price of 187. Market indecision, reflected in sideways trading near 160.61, supported the cautious call.

LPLA

Apr 10, 2026

Target

$374.00

Current

$323.46

Performance

3.50%

LPLA received a Overweight rating from Michael Cyprys on Apr 10, 2026, aiming for 374. Price action was muted, as shares hovered around 323.46 despite the bullish outlook.

MIAX

Apr 10, 2026

Target

$50.00

Current

$44.93

Performance

7.10%

On Apr 10, 2026, Michael Cyprys published a Overweight outlook on MIAX, with a target of 50. Shares gained 7.10%, underscoring the accuracy of the bullish outlook toward 50.

RJF

Apr 10, 2026

Target

$171.00

Current

$152.24

Performance

4.14%

Michael Cyprys on Apr 10, 2026 assigned RJF a Equal-Weight rating, with a price target of 171. The Hold stance reflected consolidation, as shares held near 152.24.

TW

Apr 10, 2026

Target

$138.00

Current

$115.12

Performance

-5.20%

On Apr 10, 2026, Michael Cyprys reaffirmed TW with a Equal-Weight rating, targeting 138. The Hold stance reflected market caution that was later justified.

VIRT

Apr 10, 2026

Target

$39.00

Current

$50.56

Performance

4.03%

VIRT was rated Underweight by Michael Cyprys on Apr 10, 2026, with a price objective of 39. The expected decline hasn’t materialized, as shares trade near 50.56.

AAMI

Apr 01, 2026

Target

$54.00

Current

$66.70

Performance

18.68%

On Apr 01, 2026, Michael Cyprys initiated coverage on AAMI with a Equal-Weight rating and target of 54. The Hold stance underestimated the stock’s strength as it gained 18.68%.

WT

Apr 01, 2026

Target

$16.50

Current

$18.30

Performance

26.47%

Michael Cyprys issued a Equal-Weight recommendation for WT on Apr 01, 2026, price target set at 16.5. A neutral call gave way to stronger-than-expected performance, closing in on 16.5.

VRTS

Apr 01, 2026

Target

$125.00

Current

$142.17

Performance

8.43%

On Apr 01, 2026, VRTS was evaluated by Michael Cyprys, who gave a Underweight rating and target of 125. Investors benefited from heeding the Sell stance, avoiding a 8.43% decline.

TROW

Apr 01, 2026

Target

$107.00

Current

$98.10

Performance

9.16%

Michael Cyprys rated TROW as Equal-Weight on Apr 01, 2026, setting a price target of 107. Despite the Hold call, shares climbed 9.16% to 98.1, revealing unexpected momentum.

IVZ

Apr 01, 2026

Target

$26.00

Current

$24.95

Performance

2.59%

On Apr 01, 2026, IVZ was given a Equal-Weight rating by Michael Cyprys, with a target price of 26. Market indecision, reflected in sideways trading near 24.95, supported the cautious call.

BEN

Feb 03, 2026

Target

$22.00

Current

$27.73

Performance

2.70%

BEN received a Underweight rating from Michael Cyprys on Feb 03, 2026, aiming for 22. Bearish momentum failed to push shares lower, as they hovered around 27.73.

VCTR

Feb 03, 2026

Target

$69.00

Current

$74.53

Performance

8.01%

On Feb 03, 2026, Michael Cyprys published a Equal-Weight outlook on VCTR, with a target of 69. The Hold call missed some of the bullish momentum as shares advanced toward 69.

NDAQ

Jan 30, 2026

Target

$116.00

Current

$87.78

Performance

-9.40%

Michael Cyprys on Jan 30, 2026 assigned NDAQ a Overweight rating, with a price target of 116. The call has struggled to gain traction, with shares losing 9.40%.

MKTX

Jan 15, 2026

Target

$195.00

Current

$164.96

Performance

-5.55%

On Jan 15, 2026, Michael Cyprys reaffirmed MKTX with a Equal-Weight rating, targeting 195. The Hold stance reflected market caution that was later justified.

CG

Oct 21, 2025

Target

$67.00

Current

$52.55

Performance

-9.54%

CG was rated Equal-Weight by Michael Cyprys on Oct 21, 2025, with a price objective of 67. Investors who stayed cautious avoided some of the 9.54% decline.

HLNE

Oct 21, 2025

Target

$154.00

Current

$106.83

Performance

-11.69%

On Oct 21, 2025, Michael Cyprys initiated coverage on HLNE with a Equal-Weight rating and target of 154. The rating matched the stock’s inability to hold above 106.83.

KKR

Oct 21, 2025

Target

$166.00

Current

$103.92

Performance

-15.98%

Michael Cyprys issued a Overweight recommendation for KKR on Oct 21, 2025, price target set at 166. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

STEP

Oct 21, 2025

Target

$66.00

Current

$55.16

Performance

-13.12%

On Oct 21, 2025, STEP was evaluated by Michael Cyprys, who gave a Equal-Weight rating and target of 66. The Hold call avoided chasing into subsequent weakness of 13.12%.

TPG

Oct 21, 2025

Target

$63.00

Current

$44.68

Performance

-21.24%

Michael Cyprys rated TPG as Equal-Weight on Oct 21, 2025, setting a price target of 63. The cautious Hold call aligned with subsequent weakness, as shares slipped 21.24%.

BSIG

Dec 20, 2024

Target

$25.00

Current

$26.34

Performance

-2.48%

On Dec 20, 2024, BSIG was given a Underweight rating by Michael Cyprys, with a target price of 25. The stock traded sideways with only a -2.48% move, leaving the Sell case unresolved.

BRDG

Oct 10, 2024

Target

$14.00

Current

$9.60

Performance

-6.71%

BRDG received a Overweight rating from Michael Cyprys on Oct 10, 2024, aiming for 14. The rating hasn’t played out as hoped, with the stock trading 6.71% below expectations.

PX